Provenge Significantly Extends Survival of Men With Advanced Prostate Cancer, Dendreon Says

14/04/09

Dendreon’s prostate cancer vaccine significantly prolonged the overall survival among 500 men with advanced, metastic  prostate cancer  compared to a placebo, the company said Tuesday.
Results were “robust” and “unambiguous,” a spokesman said during today’s (Tues April 14) company broadcast conference call with biotech investment analysts.
“The successful outcome from the Phase 3 IMPACT study provides validation [...] (Source: psa-rising.com/blog)

Original post by psa-rising.com/blog and software by Elliott Back

 

No Comments »

No comments yet.

RSS feed for comments on this post. TrackBack URL

Leave a comment

You must be logged in to post a comment.